The latest price target for Intra-Cellular Therapies (NASDAQ:ITCI) was reported by JP Morgan on November 4, 2024. The analyst firm set a price target for $89.00 expecting ITCI to rise to within 12 months (a possible 3.86% upside). 47 analyst firms have reported ratings in the last year.

The latest analyst rating for Intra-Cellular Therapies (NASDAQ:ITCI) was provided by JP Morgan, and Intra-Cellular Therapies maintained their overweight rating.

The last upgrade for Intra-Cellular Therapies Inc happened on September 6, 2024 when Piper Sandler raised their price target to $92. Piper Sandler previously had a neutral for Intra-Cellular Therapies Inc.

The last downgrade for Intra-Cellular Therapies Inc happened on June 25, 2024 when UBS changed their price target from $85 to $83 for Intra-Cellular Therapies Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Intra-Cellular Therapies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Intra-Cellular Therapies was filed on November 4, 2024 so you should expect the next rating to be made available sometime around November 4, 2025.

While ratings are subjective and will change, the latest Intra-Cellular Therapies (ITCI) rating was a maintained with a price target of $81.00 to $89.00. The current price Intra-Cellular Therapies (ITCI) is trading at is $85.69, which is within the analyst’s predicted range.